---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-23-000020"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2023-02-03T23:59:59+00:00"
generated_at: "2026-06-20T01:13:36.111318+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports widened Q3 net loss of $63.2M; cash $432.6M; batoclimab trials on track

## Summary
- Net loss $63.2M ($0.49/share) vs $41.4M ($0.36) prior year; R&D spend rose to $42.3M.
- Cash $432.6M expected to fund operations into second half of calendar 2025.
- Phase 1 trial of IMVT-1402 to start early 2023; initial data expected mid-2023.
- Phase 3 batoclimab in TED initiated; Phase 2b in CIDP started; topline results H1 2025 and H1 2024.
- Batoclimab development for warm AIHA discontinued; indication reserved for IMVT-1402.

## SEC filing metadata
- accession: 0001764013-23-000020
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2023-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000020/0001764013-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000020/imvt-20230203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-23-000020
- JSON: https://secwatch.observer/filing/0001764013-23-000020.json
- Plain text: https://secwatch.observer/filing/0001764013-23-000020.txt

## Key facts
- Earnings Releases
  Immunovant, Inc. reported fiscal nine months ended December 31, 2022 results: net income $151.5 million ($1.26 per common share), EPS ($1.26 per common share).
  - Period: fiscal nine months ended December 31, 2022
  - Net income: $151.5 million ($1.26 per common share)
  - EPS: ($1.26 per common share)
  - Result: reported results
  source text: Net loss was $151.5 million ($1.26 per common share) for the nine months ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000020/0001764013-23-000020-index.htm
- Earnings Releases
  Immunovant, Inc. reported fiscal third quarter ended December 31, 2022 results: net income $63.2 million ($0.49 per common share), EPS ($0.49 per common share).
  - Period: fiscal third quarter ended December 31, 2022
  - Net income: $63.2 million ($0.49 per common share)
  - EPS: ($0.49 per common share)
  - Result: reported results
  source text: Net loss was $63.2 million ($0.49 per common share) for the three months ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000020/0001764013-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.